The EPS estimate of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for quarter ended 2016-09-30 is $-1.59.
EPS projections 7 and 30 days ago were $-1.59 and $-1.59 respectively. Analysts projected $-1.59 and $-1.59 respectively as EPS 60 and 90 days ago. The projections shows a change of 0% from estimates of 7-days ago.
The EPS revisions up and down count in the preceding 7 days were 0 and 0 respectively. The count of bullish revisions in earnings in the last 1-month, 60, 90 and 120 days were 1, 1, 1 and 1.
The count of bearish revisions of EPS in the last 1-month, 60, 90 and 120 days were 0, 0, 4 and 4.
The count of EPS revisions bullish and bearish in the last 18 days were 1 and 1 respectively.
The EPS projection prior to the release of actual report for the period closed 1 is $-1.59 on basis of 9 EPS estimates. As on 2016-05-09, the reported EPS was $-1.35, showing a surprise of $-0.06 or -4.65%. It showed a standard deviation of 0.15.
Quarterly Sales Estimates
The arithmetic mean of released annual sales estimates for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is $2.505 and the median is $2.505. The estimate is calculated by 2 analysts for the fiscal 2016.
The highest annual estimate is $4.49 and the lowest estimate is $0.52. The standard deviation of given annual sales estimates is 2.807%.
As many as 2 and 2 analysts have increased and decreased sales estimate, respectively in last seven days. It shows a percentage change of 0% from the past week.
Almost 2 and 2 analysts have increased and decreased sales estimate, respectively in last one month. It shows a percentage change of 0% from last month.
The number of analysts who have upped and decreased their sales projections in the last one-quarter is 2 and 2 respectively. The change in the estimate from last quarter is 0%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...